TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO

Launched by UNIVERSITY COLLEGE, LONDON · Nov 16, 2022

Keywords

ClinConnect Summary

The TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO trial is studying how lung cancer and pleural mesothelioma change during treatment. This research aims to understand more about the disease’s evolution in patients with early and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and pleural mesothelioma. By tracking changes over time, the study hopes to improve treatment options and outcomes for patients.

To participate, individuals must be at least 18 years old and meet specific health criteria related to their cancer stage and treatment options. For example, those with early-stage NSCLC who are eligible for surgery can join the study, as well as patients with late-stage cancer who are not candidates for surgery. Participants will be asked to visit the study site every three months for the first two years and then every six months after that. During these visits, researchers will collect samples and conduct assessments to monitor the disease's progression. If you or a loved one is considering joining this trial, it could provide valuable insights into lung cancer and may contribute to future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Cohort A, B and C :
• • Written Informed consent
• • Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly.
• • Agreement to be followed up at a TRACERx EVO site
• Cohort A:
• • Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery
• • Histopathologically confirmed NSCLC, or a strong suspicion of cancer on lung imaging necessitating surgery (e.g., diagnosis determined from frozen section in theatre)
• • Primary surgery in keeping with NICE guidelines in (lobectomy, either open or thoracoscopic), lung parenchymal-sparing operations (segmentectomy or wedge resection) if a complete resection can be achieved, extensive surgery (bronchoangioplastic surgery, bilobectomy, pneumonectomy) if necessary to obtain clear margins, hilar and mediastinal lymph node sampling or en bloc resection)
• • For participants proceeding with upfront primary surgery (i.e. no neoadjuvant therapy), a minimum tumour diameter at least 15mm to allow for sampling of at least two tumour regions
• • Participants undergoing neoadjuvant treatment must have at least 1 region of fresh frozen or FFPE surgical or diagnostic biopsy tissue.
• • Considered sufficiently fit for upfront standard of care primary surgery or neoadjuvant therapy if indicated
• • Performance status 0 to 2
• Cohort B:
• • Participants ≥18 years of age, with late-stage unresectable stage IIIB and above NSCLC disease (TNM 8th edition) or presenting with stage IV de novo metastatic disease.
• • Sufficient tissue (at least 1 region/biopsy), either FFPE or fresh frozen
• • Deemed to be fit for anti-cancer treatment
• • Performance status 0 to 2 Participants who were initially consented into Cohort A with a post-surgical staging of stage IIIB/C or IV could be included in Cohort B.
• Cohort C:
• • Participants ≥18 years of age, with any stage SCLC or pleural mesothelioma.
• • Sufficient tissue (at least 1 region/biopsy), either FFPE or fresh frozen
• • Deemed to be fit for anti-cancer treatment
• • Performance status 0 to 2
• Exclusion Criteria:
• * Cohort A, B and C:
• • Other active malignancy
• • Any other\* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).
• • Any other\* current malignancy or malignancy diagnosed or relapsed within the past 3 years\*\*.
• • \*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer
• • \*\*An exception will be made for malignancies diagnosed or relapsed more than 2, but less than 3, years ago only if a pre-operative biopsy of the lung lesion has confirmed a diagnosis of NSCLC.
• • Psychological condition that would preclude informed consent
• • Diagnosis other than NSCLC, SCLC or pleural mesothelioma confirmed following surgery or biopsy
• • Confirmed diagnosis of known high-risk infections (e.g., Human Immunodeficiency Virus) (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection, tuberculosis and Creutzfeldt-Jacob disease) unless participant case is of a particular scientific interest and agreed in advance with research staff, local mortuary staff and pathologist.
• • Contra-indicated co-morbid conditions
• Cohort A:
• • Positive margins, incomplete resection or insufficient nodal sampling
• • Insufficient tissue, i.e., for participants having upfront surgery and not having neoadjuvant therapy, a minimum of two tumour regions unlikely to be obtained for the study based on pre-operative imaging. For participants having neoadjuvant therapy i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE).
• • Participant found to have pre-invasive lesions rather than invasive cancer following surgery, such as adenocarcinoma in situ or minimally invasive lesions will be withdrawn. However, the surgical tissue and baseline blood already collected will be sent to the central laboratory. These participants will not be followed-up in the study or required to provide any further blood samples. If these participants subsequently develop invasive cancer, the date of diagnosis and the tumour histology will be reported on the electronic data capture system.
• Cohort B/C:
• • • Insufficient tissue, i.e., at least one tissue biopsy to be obtained (Fresh Frozen or FFPE)